Clearbridge Health Ltd. · SGX:1H3
Clearbridge Health — Investor Presentation (September 2021)
25 slides from Clearbridge Health's investor presentation, Sep 30, 2021
Slide 1: Redefining Healthcare in Asia with Precision
REDEFINING HEALTHCARE IN ASIA WITH PRECISION
Slide 2: Important Notice
IMPORTANT NOTICE Clearbridge Health Limited (the “Company”) is a company listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (the “SGX-ST”). This presentation has been prepared by the Company and has been reviewed by the Company’s sponsor, United Overseas Bank Limited (
Slide 3: Introduction
INTRODUCTION Clearbridge Health CBMG: Medical Clinics/ Centres Healthcare Systems Medtech Investments A regional healthcare • A regional healthcare services and product distribution • Operates over 24 hemodialysis • Biolidics Limited (Biolidics), an associate group centres and 22 clinical laboratori
Slide 4: Group Structure
GROUP STRUCTURE Clearbridge Health (CBH) SGX: 1H3 Healthcare CBMG: Medical Clinics/Centres Systems Medtech Investments 80.2% 100% 100% 100% Clearbridge Medical Group (CBMG) Clearbridge Assays SAM Laboratory Clearbridge BSA Effective Effective 100% 51% 85% 100% 55% 79.8% 22.9% 1.4% Clearbridge Clearb
Slide 5: Key Milestones
KEY MILESTONES Raised S$11.5m of Convertible BUILDING A REGIONAL HEALTHCARE GROUP IN ASIA Placement of S$11.3m Preference Shares at Subsidiary Level of Shares Clearbridge Medical Group (CBMG) Raised S$11.3m to fuel raised S$11.5m by way of a convertible further expansion in preference shares for exp
Slide 6: Value Creation Process
VALUE CREATION PROCESS DRIVEN BY AN EBITDA-FOCUSED EXPANSION STRATEGY Unlocking Value Synergies Realisation Leverage Growth Value Realisation • Capitalising valuation • Maximising revenue growth by multiple differential between • Reducing cost of capital by • Building a detachable achieving economie
Slide 7: CBMG
CBMG A REGIONAL DISTRIBUTION NETWORK OF HEALTHCARE PRODUCT AND SERVICES HONG KONG PHILIPPINES ▪ Clearbridge Medical Group SINGAPORE (Hong Kong), a medical clinic in ▪ Clearbridge Medical Philippines, a 4- Causeway Bay caters to medical storey multi-specialty medical centre ▪ Medic Surgical and Laser
Slide 8: Healthcare Systems
HEALTHCARE SYSTEMS OPERATES LABORATORIES AND HEMODIALYSIS CENTRES UNDER PUBLIC-PARTNERSHIP MODEL IN INDONESIA IGM Labs • Jointly operate 22 laboratories and patient care facilities with public and private hospitals RSUH Adam Malik RSU Dr. Zainoel Abidin Sanglah General Hospital • 5 of the partnering
Slide 9: Financial Highlights
FINANCIAL HIGHLIGHTS Revenue (S$’000) 1H21 REVENUE GREW 9.6% TO S$16.2M FROM S$14.8M 25,000 21,459 IN 2H20 20,000 16,216 14,680 14,799 15,000 KEY HIGHLIGHTS 10,000 6,853 4,302 5,000 • The Group’s revenue grew 9.6% in 1H21 to S$16.2m, compared to S$14.8m in 1,833 2H20 as core businesses gradually rec
Slide 10: Recent Developments: Convertible Preference Shares Raised by CBMG
RECENT DEVELOPMENTS RAISED S$11.5 MILLION OF CONVERTIBLE PREFERENCE SHARES BY CLEARBRIDGE MEDICAL GROUP (CBMG) • The Group’s subsidiary, CBMG has successfully raised S$11.5 million by issuing convertible preference shares in March 2021. • The convertible preference shares will be converted into ordi
Slide 11: Recent Developments: Disposal of Clearbridge Biophotonics
RECENT DEVELOPMENTS DISPOSAL OF CLEARBRIDGE BIOPHOTONICS PTE. LTD. (“CBBP”) • In line with the Group’s EBITDA-focused strategy, the Group has successfully disposed of Clearbridge Biophotonics Pte. Ltd. (“CBBP”), a non-core subsidiary in the business of manufacturing of optical instruments and photog
Slide 12: Recent Developments: Partial Early Redemption of Convertible Bonds
RECENT DEVELOPMENTS PARTIAL EARLY REDEMPTION OF CONVERTIBLE BONDS AND EXTENSION OF MATURITY DATE OF THE REMAINING CONVERTIBLE BONDS • On 17 September 2021, the Group announced that it will partial early redeem S$3.5 million in principal amount of convertible bonds on a pro rata basis which will redu
Slide 13: Recent Developments: Introducing Sinopharm COVID-19 Vaccine to Singapore
RECENT DEVELOPMENTS INTRODUCING SINOPHARM COVID-19 VACCINE TO SINGAPORE • In late August 2021, the Group has successfully imported its first batch of SARS-CoV-2 Vaccine (Vero Cell), Inactivated or COVID-19 Vaccine (Vero Cell), Inactivated, also known as COVID-19 Vaccine BIBP (the "Sinopharm COVID-19
Slide 14: Merits of Clearbridge Health
MERITS OF CLEARBRIDGE HEALTH Direct proxy to the defensive Global trend of precision Differentiated business strategy Ecosystem of complementary and high-growth healthcare medicine underpins the by building the first broad business components with industry in Asia industry’s strong prospects and bas
Slide 15: Appendix
APPENDIX
Slide 16: Management Team
MANAGEMENT TEAM JEREMY YEE JONATHAN LIAU SIMON HOO FEXLICIA LEE Executive Director Chief Operating Chief Business Financial Controller and CEO Officer Officer • FormerCEO-Cordlife • FormerVPInvestments- • Former CEO - Life • Former FC - LifeCorporation GroupLimited(SGX-listed) EDBI Corporation Servi
Slide 17: CBMG: Singapore
CBMG: SINGAPORE AESTHETICS, MEDICAL & DENTAL CLINICS Dr Loo & therapists Aesthetics & medical Treatment room Clinics located at clinic at outskirts of heartlands CBD 17
Slide 18: CBMG: Singapore - Sinopharm COVID-19 Vaccine
CBMG: SINGAPORE ONE OF THE FIRST HEALTHCARE INSTITUTIONS TO ADMINISTER THE SINOPHARM COVID-19 VACCINE IN SINGAPORE Introduce Sinopharm COVID-19 vaccine in our Singapore clinic to accelerate Singapore’s vaccination rates. 18
Slide 19: CBMG: Philippines
CBMG: PHILIPPINES MULTI-SPECIALTY MEDICAL CENTRE AND CLINICS 4-storey medical Hemodialysis centre Covid-19 testing In-house pharmacy centre services 19
Slide 20: CBMG: Philippines
CBMG: PHILIPPINES MULTI-SPECIALTY MEDICAL CENTRE AND CLINICS Cone Beam CT Scan Adult/ Ortho Dentistry Marketing with Social Treatment room Pediatric Influencers 20
Slide 21: CBMG: Hong Kong
CBMG: HONG KONG CLEARBRIDGE MEDICAL HONG KONG Medical clinic located at Causeway Bay, Healthcare seminar conducted at clinic Hong Kong 21
Slide 22: Healthcare Systems in Indonesia: IGM Labs
HEALTHCARE SYSTEMS IN INDONESIA PT INDO GENESIS MEDIKA (IGM LABS) RSUP. Dr. Mohammad RS Cipto Mangunkusumo RS Umum Pusat Sanglah RS Umum Pusat H. Adam RSUD Dr. Zainoel RSUD Kabupaten Badung Hoesin Palembang Denpasar Bali Malik Medan Abidin Banda Aceh RS Jogja International Rumah Sakit Universitas RS
Slide 23: Healthcare Systems in Indonesia: IGM Labs
HEALTHCARE SYSTEMS IN INDONESIA PT INDO GENESIS MEDIKA (IGM LABS) Cash flows are highly recurring as services are essential in nature Services are reimbursed by Indonesia health coverage program (BPJS) Joint operation contracts are typically 5-7 years with revenue sharing ratio of 55% to 70% to IGM
Slide 24: Healthcare Systems in Indonesia: TMJ
HEALTHCARE SYSTEMS IN INDONESIA PT TIRTA MEDIKA JAYA (TMJ) Cash flows are highly recurring as patients undergo approximately 3 hemodialysis treatments/ week Services are reimbursed by Indonesia health coverage program (BPJS) Joint operation contracts are typically 7-10 years with revenue sharing rat
Slide 25: End of Presentation
END OF PRESENTATION Tel: 6251 0136 Add: 37 Jalan Pemimpin #08-05 Mapex Singapore 577177
Clearbridge Health — Investor Presentation (September 2021) on 6ix